Loading...

Expect a future valuation of 22x as AstraZeneca bets on pipeline strength

Published
04 Feb 25
Updated
30 Apr 25
n/a
n/a
Unike's Fair Value
n/a
Loading
1Y
20.7%
7D
4.2%

Author's Valuation

SEK 1.67k0.5% overvalued intrinsic discount

Unike's Fair Value

Shared on 30 Apr 25

Fair value Decreased 35%

Unike has decreased revenue growth from 9.9% to 8.0%.

Shared on 08 Mar 25

Fair value Increased 0.50%

Unike has increased profit margin from 25.0% to 28.0%.

Shared on 05 Feb 25

Unike made no meaningful changes to valuation assumptions.